360° UPSC Mains Analysis

India and United Kingdom

India's climate is dominated by the tropical monsoon system, making its water- and energy-intensive industrial sectors highly sensitive to climate variability. The UK's temperate maritime climate and its commitment to net-zero emissions drive its domestic carbon pricing policies, such as the UK Emissions Trading Scheme (ETS) and the upcoming Carbon Border Adjustment Mechanism (CBAM) starting January 1, 2027, aimed at preventing carbon leakage.

India occupies a strategic peninsular position in South Asia, commanding key Sea Lines of Communication (SLOCs) in the Indian Ocean, while the United Kingdom is an archipelago in northwestern Europe. Bilateral trade between these two nations relies heavily on the maritime route passing through the Suez Canal, Red Sea, and the Mediterranean Sea, making these maritime choke points highly significant for their trade security.

India is a global manufacturing hub for low-cost generic medicines and carbon-intensive commodities like steel and aluminium. The UK is a major consumer of these resources but imposes strict environmental and intellectual property standards, creating trade friction between India's resource-exporting economy and the UK's high-value service and technology-driven market.

Under the Seventh Schedule of the Constitution of India, 'Entering into treaties and agreements with foreign countries' (Entry 14) and 'Trade and commerce with foreign countries' (Entry 41) fall exclusively under List I (Union List). Consequently, the Central Government holds sole legislative and executive competence over negotiating and implementing the India-U.K. CETA. However, domestic implementation of trade commitments can intersect with State List subjects like Public Health (Entry 6, List II), requiring cooperative federalism.

The CETA eliminates tariffs on 99% of Indian exports, significantly boosting bilateral trade with the UK. However, the trade balance gains could be diluted after January 1, 2027, when the UK's CBAM imposes carbon taxes on Indian steel and aluminium. Additionally, the UK's pharmaceutical exports to India will remain restricted to just 0.5% of its global exports due to India's stringent intellectual property standards.

The India-U.K. CETA, which entered into force on July 15, 2026, cuts tariffs on 99% of Indian exports, which is expected to boost GDP growth and improve the current account balance. However, the exclusion of a Bilateral Investment Treaty (BIT) and the upcoming UK Carbon Border Adjustment Mechanism (CBAM) starting January 1, 2027, could limit foreign direct investment (FDI) inflows and increase compliance costs for carbon-intensive exports, partially offsetting these macroeconomic gains.

The secondary (manufacturing) and tertiary (services) sectors are heavily impacted. The domestic pharmaceutical industry benefits from the retention of Section 3(d) of the Patents Act, 1970, protecting generic manufacturers from evergreening. Conversely, the metal manufacturing industries (steel and aluminium) face downside risks due to the UK's CBAM starting in 2027, which will impose carbon levies on these carbon-intensive exports.

The deal will positively impact employment and wages in export-oriented sectors like textiles, leather, and professional services due to eased mobility rules. However, the lack of investment protections under a formal BIT may slow down greenfield job creation from UK-based firms. Consumer prices for imported UK goods may decrease slightly due to tariff cuts, while domestic healthcare costs remain low due to protected generic drug manufacturing.

India's post-independence economic policy was deeply shaped by colonial-era exploitation, leading to a strong emphasis on economic sovereignty and self-reliance. The enactment of the Patents Act, 1970, marked a conscious departure from colonial patent laws by abolishing product patents in pharmaceuticals to foster a domestic generic drug industry. Similarly, India's historical skepticism toward international arbitration stems from a desire to protect sovereign regulatory space from foreign capital interference, a sentiment rooted in the Constituent Assembly debates on property rights and state sovereignty.

Following the 1991 economic reforms, India actively signed Bilateral Investment Treaties (BITs) to attract foreign capital, but a series of adverse international arbitration awards, notably the White Industries case in 2011, prompted a major policy shift. This led to the formulation of the restrictive 2015 Model BIT, which mandated the exhaustion of local remedies for at least five years under Article 15 before seeking international arbitration, and the subsequent unilateral termination of over 70 existing BITs in 2017. In parallel, India's intellectual property regime transitioned to comply with the WTO's TRIPS Agreement through the Patents (Amendment) Act, 2005, which introduced product patents but incorporated strict safeguards like Section 3(d) to prevent patent evergreening and protect public health.

The tension between protecting domestic industries and integrating with global trade regimes is reminiscent of India's stance during the Uruguay Round of GATT negotiations (1986–1994), where India strongly resisted Western pressure on intellectual property and services to safeguard its sovereign developmental interests. Similarly, the current dispute over the UK's Carbon Border Adjustment Mechanism (CBAM) mirrors historical North-South environmental debates, such as those during the 1992 Rio Earth Summit, where developing nations argued against unilateral green trade barriers under the principle of Common but Differentiated Responsibilities (CBDR).

The insistence on protecting domestic generic manufacturing and resisting foreign investment arbitration echoes the Swadeshi Movement (1905), which championed indigenous industries (Swadeshi) and self-reliance as a counterweight to British economic exploitation and colonial legal structures.

The exclusion of the UK's Carbon Border Adjustment Mechanism (CBAM) from the trade deal pressures India's carbon-intensive sectors like steel, aluminium, and cement to decarbonize. This transition can indirectly reduce local ecological degradation, industrial pollution, and resource extraction in ecologically sensitive mining regions of India, such as the Central Indian tribal and forest belts.

The trade friction over Section 3(d) of the Patents Act, 1970 highlights the scientific challenge of balancing pharmaceutical innovation with public health. Additionally, bypassing the UK's CBAM will require Indian heavy industries to adopt advanced green technologies, such as Green Hydrogen-based Direct Reduced Iron (DRI) for steelmaking and Carbon Capture, Utilisation, and Storage (CCUS).

The UK's CBAM, effective January 1, 2027, aims to prevent 'carbon leakage' by taxing carbon-intensive imports. This mechanism incentivizes Indian exporters to accelerate industrial decarbonization, aligning with India's updated Nationally Determined Contributions (NDCs) under the Paris Agreement to reduce the emissions intensity of its GDP by 45% by 2030 from 2005 levels.

The trade dynamics directly influence SDG 13 (Climate Action) by driving industrial emission reductions, SDG 9 (Industry, Innovation, and Infrastructure) through the adoption of clean, energy-efficient technologies, and SDG 12 (Responsible Consumption and Production) by encouraging sustainable manufacturing practices in heavy industries.

The trade deal directly impacts the daily lives of millions by keeping life-saving medicines affordable, thereby preserving the dignity and health of patients who rely on generic drugs. However, for workers in the steel and aluminium industries, the impending 2027 CBAM carbon tax threatens their livelihoods and economic stability if Indian exports become uncompetitive. Furthermore, the absence of a Bilateral Investment Treaty (BIT) may slow down foreign capital inflows, indirectly affecting job creation and infrastructure development that improve citizens' standard of living.

The preservation of strict patent standards under Section 3(d) of the Patents Act, 1970 upholds the Right to Life and Health under Article 21 of the Constitution of India. Furthermore, India's stance on investment and patent regulation aligns with Article 39(b) and (c) of the Directive Principles of State Policy (DPSP), which mandate that the State direct its policy toward ensuring that the ownership and control of material resources subserve the common good and prevent the concentration of wealth.

A policymaker faces the ethical conflict of 'Development vs. Welfare Rights,' where attracting foreign capital through relaxed investment treaties must be balanced against protecting domestic judicial sovereignty and the public's right to affordable healthcare. Additionally, there is a conflict of 'Intergenerational Equity vs. Immediate Livelihoods,' as enforcing strict carbon-reduction measures to bypass the UK's CBAM protects the environment but threatens the immediate survival and employment of MSME workers in carbon-intensive sectors.

The retention of Section 3(d) of the Patents Act, 1970 directly protects economically weaker sections (EWS), the elderly, and rural populations by preventing the 'evergreening' of pharmaceutical patents. This ensures the continued availability of low-cost generic medicines, preventing these vulnerable groups from falling into deep medical debt due to high out-of-pocket expenditure. Conversely, the lack of investment protections and the imposition of the UK's Carbon Border Adjustment Mechanism (CBAM) could lead to job losses in carbon-intensive sectors like steel and aluminium, disproportionately affecting low-skilled industrial laborers.